Yes it sucked. But there's little medium term risk here. There trading just a bit over cash at these levels.... over 50 million in the bank with 100 million market cap. Positive catalysts ahead including end of phase II ovarian meeting and thyroid data near year's end, so plenty of time to bail at higher prices if so desired. The big tuna will be next year with rGBM. I've fluctuated between mania and panic with VBLT over the past several months. How can I be right about VB-111 with glioblastoma when everyone discounts any value? That's the bottom line for me. I've reviewed the data and I think I'm right and Adam F. et al are wrong. Only time will tell.
News 
Market Data 
Discover 
